Expression And Clinical Significance Of ERCC1、β-tubulin Ⅲ、TS And TOPO Ⅱα In Infiltrating Breast Cancer

Background Breast cancer is one of the common malignancy of women, and it is a heterogeneous tumor, including a variety of special pathological features and biological behavior,and invasive breast cancer is the major histological type of breast cancer.Chemotherapy plays an important role in the treatment of breast cancer,Nowadays chemotherapeutic drugs have been proven effective against breast cancer, but clinical evidence suggests that there are individual differences in breast cancer patients on chemotherapy response, which means not all breast cancer patients can benefit from the same chemotherapy regiment, and the reason for this difference is that the differential expression of genes. Differentially expressed genes finally correspond to the change of amount in the expression of encoded proteins within the tissue,this also resulted in tumor heterogeneity and the tumor sensitivity to different chemotherapeutic drugs in different patients, so choosing the right chemotherapeutic drugs is particularly important. Studies have shown that the expression of ERCC1, β-tubulin Ⅲ, TS, TOPO Ⅱα in breast cancer were related to the sensitivity of some chemotherapy drug such as platinum, paclitaxel,5-fluorouracil and anthracycline.Objective To detect the expression and clinical significance of ERCC1, β-tubulin Ⅲ, TS, TOPO Ⅱa in invasive breast cancer, to investigate whether their expressions can guide the individual treatment of breast cancer.Methods From September2011to April2013,53cases of women patients with infiltrating breast cancer were enrolled in our study in Department of Breast and Thyroid Surgery in Qianfoshan Hospital. ERCC1、β-tubulin ⅢTS and TOPO Ⅱα were tested in the patients with invasive breast cancer.And, the correlations between the expressions and clinicopathological features including tumor size, degree of infiltration, TNM stage, lymph node metastasis, ER and PR expression levels were analyzed.The positive results criteria:positive cells less than5%is regarded as negative,5%to25%is regarded as+(weak positive),25%to50%is regarded as++(positive), more than50%is regarded as+++(strong positive). And++or+++were high expression,-or+were low expression. SPSS17.0system was used for statistical analysis.Results1.Among53cases of infiltrating breast cancer patients, the low expression rate for ERCC1was75.47%(40/53),for β-tubulin III the low expression rates was54.71%(29/53);for TS the low expression rates was79.24%(44/53);for TOPO Ⅱα the high expression rates was45.28%(24/53).2.1The expression of ERCC1was low in patients with negative lymph node metastasis and positive ER and PR;2.2The low expression of6-tubulin Ⅲ had no related with all the clinicopathological features (p>0.05);2.3The low expression of TS is corelated with TNM stage and positive of ER (p<0.05);2.4The high expression of TOPO Ⅱα is correlated with tumor size、positive lymph node and positive ER and PR(p<0.05).3There were no correlation between the expression of ERCC1,β-tubulin Ⅲ, TS and TOPO Ⅱα.(p>0.05).Conclusion1The low expression of ERCC1suggested that the expression of ERCC1was low in well-differentiated breast cancer, patients were more likely to benefit from chemotherapy regimens containing platinum.2The low expression of β-tubulin Ⅲ suggested that the β-tubulin Ⅲ did not afford a major role during the occurrence or development of invasive breast cancer,we should accord to the actual situation to select chemotherapy regimens containing paclitaxel.3The low expression of TS suggested that low expression of TS was an important factor which lead to the occurrence and development of invasive breast cancer,most invasive breast cancer patients can benefit from chemotherapy regimens containing5-Fu.4The high expression of TOPO Ⅱα suggested that TOPO Ⅱα was related with the growth and metastasis of invasive breast cancer, indicated that patients with higher degree of malignancy can benefit from chemotherapy regimen containing anthracycline.